Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
20 results
D1.452 - Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study
D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review
D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials
D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy
D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update
D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre
D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study
D1.451 - Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma
D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis
D1.189 - Does Allergen Immunotherapy Add Clinically Meaningful Benefit in Paediatric Asthma and Allergic Rhinitis? A 36-Month Real-World Comparison
D1.192 - Combined Polymerized Pollen and Animal Dander Immunotherapy Improves Rhinoconjunctivitis and Asthma in Polysensitized Patients: Real-World Evidence
D1.194 - Real-World Effectiveness of Polymerized Dog Allergen Immunotherapy in Allergic Rhinoconjunctivitis and Asthma
D1.195 - Fc-Engagers as a targeted approach for antigen-specific immune inhibition in HDM allergy
D1.197 - Safety and efficacy of a modified one-day ultra-rush protocol for the induction of Hymenoptera venom immunotherapy in patients with anaphylaxis in Switzerland
D1.186 - Three years treatment with HDM injection allergen immunotherapy, omalizumab, or combination therapy in allergic asthma
D1.187 - A Novel Volume-Reduced Desensitization Protocol for Pembrolizumab Hypersensitivity in Advanced Lung Cancer
D1.188 - Adverse Reactions During Honey Bee Venom Immunotherapy as an Indicator of Underlying Clonal Mast Cell Disease Independent of Baseline Serum Tryptase: A Case Report
D1.191 - Respiratory bacterial lysate (OM-85)-loaded dissolving microneedle array patch modulates HDM-induced allergic airway inflammation and airway hyperresponsiveness in a murine asthma model
D1.198 - Efficacy of Cat Allergen Immunotherapy: A Multicenter Prospective Study
D1.199 - Severe vernal keratoconjunctivitis with allergic rhinitis treated with house dust mite (HDM) sublingual immunotherapy (SLIT)
Download the app
The congress at your fingertips
Available on
Download